Chester County News and Community Website
WILMINGTON, DE — AstraZeneca (NYSE: AZN) and Daiichi Sankyo’s Enhertu extended median progression-free survival by six months versus pembrolizumab plus chemotherapy in a Phase III trial of first-line treatment for …
Enhertu Extends PFS by Six Months in HER2 Lung Cancer Read More WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) Tagrisso showed a sustained survival benefit eight years after treatment in a Phase III trial of patients with early-stage EGFR-mutated non-small cell lung cancer, …
Tagrisso Cuts Death Risk 47% in Long-Term Lung Cancer Trial Read More WILMINGTON, DE — AstraZeneca’s Imfinzi combined with Amgen’s tarlatamab significantly extended overall survival in a Phase III trial of first-line extensive-stage small cell lung cancer, potentially expanding treatment options for …
AstraZeneca Lung Cancer Combo Extends Survival in Phase III Read More WILMINGTON, DE — AstraZeneca’s experimental COPD drug tozorakimab reduced moderate and severe exacerbations by as much as 34% in two Phase III trials across a broad patient population, supporting a …
AstraZeneca COPD Drug Cuts Exacerbations in Phase III Read More WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) ETCAMAH (camizestrant) combination won accelerated U.S. approval for certain advanced breast cancer patients whose tumors develop an ESR1 mutation during first-line therapy, allowing treatment …
FDA Clears AstraZeneca Breast Cancer Regimen on Early Detection Read More WILMINGTON, DE — AstraZeneca (NYSE: AZN) completed an exclusive licensing agreement for ZEGFROVY, gaining worldwide development and commercialization rights to the lung cancer drug in a deal that includes $600 …
AstraZeneca Secures ZEGFROVY Rights in Up to $1.5B Deal Read More WILMINGTON, DE — AstraZeneca and Amgen’s TEZSPIRE met both primary endpoints in a Phase III trial of patients with eosinophilic esophagitis, extending the drug’s efficacy into a third inflammatory disease …
AstraZeneca, Amgen Drug Hits Phase III EoE Goals Read More WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported positive Phase III results for ENHERTU in first-line treatment of advanced HER2-mutant non-small cell lung cancer, potentially positioning the drug to move …
AstraZeneca, Daiichi Sankyo Eye Earlier ENHERTU Use Read More WILMINGTON, DE — AstraZeneca’s experimental antibody-drug conjugate sonesitatug vedotin improved overall survival in a Phase III trial of previously treated CLDN18.2-positive advanced gastric and related cancers, potentially broadening targeted treatment …
AstraZeneca Drug Extends Survival in Advanced Gastric Cancer Read More WILMINGTON, DE — AstraZeneca and YMCA of the USA formed a five-year partnership to expand cancer screening education, early detection awareness and survivorship support, aiming to reach 175,000 people in …
AstraZeneca, YMCA Target Cancer Screening Gap in Five-Year Push Read More